Long-term effect of imidapril hydrochloride compared with dilazep hydrochloride administration on blood pressure and renal function in patients with chronic glomerulonephritis

International Heart Journal

Volumn 46, Issue 4, 2005, Pages 701-710

  Satonaka, Hiroshi ^a   Suzuki, Etsu ^a   Hayakawa, Hiroshi ^a   Nishimatsu, Hiroaki ^a   Nagata, Daisuke ^a   Oba, Shigeyoshi ^a   Kamijo, Atsuko ^a   Takeda, Ryo ^a   Takahashi, Masao ^a   Yamamoto, Yuji ^a   Kimura, Kenjiro ^a   Hirata, Yasunobu ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

ACE inhibitor; Antiplatelet agent; IgA nephropathy

Indexed keywords

ANTITHROMBOCYTIC AGENT; CREATININE; DILAZEP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; PROTEIN; IMIDAZOLIDINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; FEMALE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; CHRONIC DISEASE; DRUG COMBINATION; DRUG EFFECT; GLOMERULONEPHRITIS; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; RENOVASCULAR HYPERTENSION; URINE;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CHRONIC DISEASE; DILAZEP; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS; HUMANS; HYPERTENSION, RENAL; IMIDAZOLIDINES; KIDNEY; MALE; MIDDLE AGED; PROTEINURIA;

EID: 33644875150     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.46.701     Document Type: Article

References (21)

1. Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of Dec. 31, 2002). J Jpn Soc Dial Ther 2004; 37: 1-24. (Japanese)
2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-62.
3. Maschio G, Alberti D, Janin G; et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-45.
4. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63.
5. Usami T, Nakao N, Fukuda M, et al. Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. Kidney Int 2003; 64: 1445-9.
6. Yoneda H, Toriumi W, Ohmachi Y. Okumura F, Fujimura H, Nishiyama S. Involvement of angiotensin II in development of spontaneous nephrosis in Dahl salt-sensitive rats. Eur J Pharmacol 1998; 362: 213-9.
7. Kashiwagi M, Shinozaki M, Hirakata H, et al. Locally activated renin-angiotensin system associated with TGF-s1 as a major factor for renal injury induced by chronic inhibition of nitric oxide synthase in rats. J Am Soc Nephrol 2000; 11: 616-24.
8. Katayama S, Kikkawa R, Isogai S, et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: A randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract 2002; 55: 113-21.
9. Inage H, Koyama A, Narita M, Tojo S. Effects of the antiplatelet agents, dipyridamole and dilazep dihydrochloride, on in vivo Platelet function and proteinuria. Jpn J Nephrol 1985; 27: 1261-70.
10. Koide H, Totsuka Y, Sugisaki T, et al. Clinical effect of the anti-platelet drug, dilazep dihydrochloride, in patients at the microalbuminuric stage of diabetic nephropathy - a multi-center study. Jpn J Nephrol 1995; 37: 644-8.
11. Nakamura T, Ushiyama C, Shimada N, et al. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care 2000; 23: 1168-71.
12. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory. a paradigm shift in nephrology. Kidney Int 1996; 49: 1774-7. (Review)
13. Keane WF. Proteinuria: Its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35: S97-105. (Review)
14. Ruggenenti P, Perna A, Mosconi L, et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int Suppl 1997; 63: S54-7.
15. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS Jr, Rovin BH. Renoprotection: One or many therapies? Kidney Int 2001; 59: 1211-26. (Review)
16. Zoja C, Morigi M, Remuzzi G. Proteinuria and phenotypic change of proximal tubular cells. J Am Soc Nephrol 2003; 14 (Suppl 1): S36-41.
17. Ruggenenti P, Perna A, Remuzzi G. GISEN Group Investigators. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-61.
18. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-62.
19. Nakamura T, Ushiyama C, Takahashi Y, et al. Effect of dilazep dihydrochloride on urinary albumin excretion in patients with autosomal dominant polycystic kidney disease. Nephron 2001; 88: 80-2.
20. Yoshida H, Kanatsu K, Muso E, et al. Effects of an anti-platelet drug (dilazep) in IgA nephropathy: Comparison of clinical effects with renal biopsy findings. Jpn J Nephrol 1994; 36: 339-44.
21. Gohda T, Makita Y, Shike T, Funabiki K, Shirato I, Tomino Y. Dilazep hydrochloride, an antiplatelet drug, inhibits lipopolysaccharide-induced mouse mesangial cell IL-6 secretion and proliferation. Kidney Blood Press Res 2001; 24: 33-8.